

## Placement Under Share Purchase Plan Shortfall

- Actinogen raises a further \$560,000
- Funds raised from US specialist biotech investor, **Biotechnology Value Fund LP (BVF)** and one of Australia's largest wealth managers, **Australian Ethical Investment**
- BVF will hold 19.97% of Actinogen and continue to be the largest shareholder on the register
- Total of \$16.5m raised through recent Placements and SPP
- Funds to drive development of Xanamem

**Sydney, 17 July 2018: Actinogen Medical (ASX: ACW or the Company)** is pleased to advise that it has received commitments for the placement of 11,200,000 fully paid ordinary shares at \$0.05 per share, to raise a further \$560,000.

The placement is being made under the shortfall of shares not subscribed for under the Share Purchase Plan (SPP) and has received support from existing investors, including US specialist biotech investor, **Biotechnology Value Fund LP (BVF)** and a leading Australian institutional investor, **Australian Ethical Investment**. The SPP shortfall placement was led by Bell Potter Securities Limited.

Following on from the placement in late May 2018 that raised \$15m, both BVF and Australian Ethical have opted to subscribe for additional shares under the SPP shortfall. After this latest placement, BVF will hold 19.97% of the Company and continue to be the largest shareholder on the register.

This placement brings the total capital raised to \$16.5m, including the \$15m Placement that saw the initial participation from BVF, Australian Ethical, and Platinum Asset Management (announced 31 May 2018) and the SPP that raised a total of \$952,500 (completed and announced on 12 July 2018).

The funds will be used to drive the development of Xanamem, which includes undertaking additional studies to enhance the dataset to support the treatment of Alzheimer's disease and cognitive deficiency associated with other neurological and metabolic diseases.

CEO of Actinogen Medical, Dr Bill Ketelbey commented: "We're delighted that both BVF and Australian Ethical have chosen to further invest in the business and in our ongoing development of Xanamem. Their commitment is a testament to the achievements we have made to date and affirms confidence in the potential of Xanamem in the treatment of this devastating disease."

**ENDS**

### Actinogen Medical

Dr. Bill Ketelbey  
CEO & Managing Director  
P: +61 2 8964 7401  
E: [bill.ketelbey@actinogen.com.au](mailto:bill.ketelbey@actinogen.com.au)

 @BillKetelbey

### Media Enquires

Zena Chamas  
Media & Capital Partners  
M: +61 434 153 055  
E: [zena.chamas@mcpartners.com.au](mailto:zena.chamas@mcpartners.com.au)

## **About Actinogen Medical**

Actinogen Medical (ASX: ACW) is an ASX-listed biotech company focused on innovative approaches to treating cognitive decline that occurs in chronic neurodegenerative and metabolic diseases. Actinogen Medical is developing Xanamem a promising new therapy for Alzheimer's disease, a condition with a multibillion dollar market potential. In the US alone, the cost of managing Alzheimer's disease is estimated to be US\$250bn, and is set to increase to US\$2tn by 2050, outstripping the treatment costs of all other diseases. Alzheimer's disease is now the leading cause of death in the UK and second only to ischaemic heart disease in Australia

## **About Xanamem™**

Xanamem's novel mechanism of action sets it apart from other Alzheimer's treatments. It works by blocking the excess production of cortisol - the stress hormone – through the inhibition of the 11β-HSD1 enzyme in the brain. This enzyme is highly concentrated in the hippocampus and frontal cortex, the areas of the brain most affected by Alzheimer's disease. There is a strong association between chronic stress and excess cortisol that leads to changes in the brain affecting memory, and to the development of amyloid plaques and neural death – all hallmarks of Alzheimer's disease.

## **About XanADu**

XanADu is a Phase II double-blind, 12-week, randomised, placebo-controlled study to assess the safety, tolerability and efficacy of Xanamem in subjects with mild dementia due to Alzheimer's disease. XanADu, will enrol 174 patients at 20 research sites across Australia, the UK and the USA. The trial is registered on [www.clinicaltrials.gov](http://www.clinicaltrials.gov) with the identifier: NCT02727699, where more details on the trial can be found, including the study design, patient eligibility criteria and the locations of the study sites.

**Actinogen Medical encourages all current investors to go paperless by registering their details with the designated registry service provider, Link Market Services.**